featured
Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Allergy and Clinical Immunology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies
J. Allergy Clin. Immunol 2022 Oct 01;[EPub Ahead of Print], E Guttman-Yassky, JP Thyssen, JI Silverberg, KA Papp, AS Paller, S Weidinger, HC Hong, B Hendrickson, D Dilley, AR Tenorio, B Ladizinski, AD Chu, J Liu, AD IrvineFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.